Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACLIFORM-COPD: Aclidinium/Formoterol FDC in COPD
NCT01462942Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2011
- Primary completion
- Jan 2013
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 22
01
Overview
A Phase 3 trial of aclidinium bromide + formoterol fumarate in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started Oct 2011; status: completed.
02
Drugs
aclidinium bromide + formoterol fumarate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01462942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01462942.